Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Adagene Inc. - ADS, each representing 1.25 ordinary shares (NQ:ADAG)

1.765 +0.135 (+8.28%)
Streaming Delayed Price Updated: 1:06 PM EDT, May 23, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 54,062
Open 1.550
Bid (Size) 1.750 (45)
Ask (Size) 1.780 (1)
Prev. Close 1.630
Today's Range 1.550 - 1.800
52wk Range 1.325 - 3.581
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug (ADG126) in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at the American Society of Clinical Oncology (ASCO) Annual Meeting
From Adagene Inc.
Via GlobeNewswire
Adagene Appoints John Maraganore, Ph.D. as Executive Advisor
From Adagene Inc.
Via GlobeNewswire

Performance

YTD
-14.3%
-14.3%
1 Month
+21.7%
+21.7%
3 Month
-13.5%
-13.5%
6 Month
-21.9%
-21.9%
1 Year
-32.4%
-32.4%

More News

Read More
Adagene Announces Upcoming Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at American Society of Clinical Oncology (ASCO) Annual Meeting
From Adagene Inc.
Via GlobeNewswire
Adagene to Present at Stifel’s 2025 Virtual Targeted Oncology Forum
From Adagene Inc.
Via GlobeNewswire
Adagene Reports Full Year 2024 Financial Results and Provides Corporate Update
From Adagene Inc.
Via GlobeNewswire
Adagene to Present at 11th Annual Immuno-Oncology 360⁰ Summit
From Adagene Inc.
Via GlobeNewswire
Adagene to Present at Leerink’s Global Healthcare Conference 2025
From Adagene Inc.
Via GlobeNewswire
Adagene Announces Investigator Initiated Phase 2 Trial for Neoadjuvant Muzastotug (ADG126) in Colorectal Cancer
From Adagene Inc.
Via GlobeNewswire
Adagene Announces Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium
From Adagene Inc.
Via GlobeNewswire
Adagene to Announce Updated Data from Phase 1b/2 Study of Muzastotug in Combination with KEYTRUDA® (pembrolizumab) in Colorectal Cancer at ASCO Gastrointestinal Cancers Symposium
From Adagene Inc.
Via GlobeNewswire
Adagene to Host Virtual KOL Event to Discuss Anti-CTLA-4 SAFEbody® ADG126 in Advanced/Metastatic Microsatellite-Stable (MSS) Colorectal Cancer (CRC) on January 25, 2025
From Adagene Inc.
Via GlobeNewswire
Adagene Presents Two Posters with New Insights on Increased Therapeutic Index for Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) and Data Reinforcing Clinical Safety and Efficacy for ADG126 as Monotherapy and in Combination with Anti-PD-1 Therapy at
From Adagene Inc.
Via GlobeNewswire
Adagene Announces Upcoming Poster Presentations on Masked Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
From Adagene Inc.
Via GlobeNewswire
Why Exicure Shares Are Trading Higher By Over 49%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Adagene Presents Results at ESMO Congress that Show Best-in-Class Therapeutic Potential for Anti-CTLA-4 SAFEbody® ADG126 (Muzastotug) in Combination with KEYTRUDA® (Pembrolizumab) in Advanced/Metastatic Microsatellite-stable (MSS) Colorectal Cancer (CRC)
From Adagene Inc.
Via GlobeNewswire
Adagene to Participate in Investor Conferences in September
From Adagene Inc.
Via GlobeNewswire
Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update
From Adagene Inc.
Via GlobeNewswire
Adagene Announces Poster Presentation on Masked Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with Pembrolizumab in MSS CRC at Upcoming European Society for Medical Oncology (ESMO) Congress in September
From Adagene Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
Adagene to Present at Investor Conferences in June
From Adagene Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Adagene Reports Full Year 2023 Financial Results and Provides Corporate Update
From Adagene Inc.
Via GlobeNewswire
Adagene Appoints Heinz-Josef Lenz, M.D., FACP to Scientific and Strategic Advisory Board
From Adagene Inc.
Via GlobeNewswire
Adagene to Present at the Leerink Partners Global Biopharma Conference 2024
From Adagene Inc.
Via GlobeNewswire
Adagene Announces Progress and Expansion of Clinical Collaboration Program for Masked, Anti-CTLA-4 SAFEbody® ADG126 (muzastotug) in Combination with KEYTRUDA® (pembrolizumab) to Demonstrate Further Efficacy in Patients with Metastatic
From Adagene Inc.
Via GlobeNewswire

Frequently Asked Questions

Is Adagene Inc. - ADS, each representing 1.25 ordinary shares publicly traded?
Yes, Adagene Inc. - ADS, each representing 1.25 ordinary shares is publicly traded.
What exchange does Adagene Inc. - ADS, each representing 1.25 ordinary shares trade on?
Adagene Inc. - ADS, each representing 1.25 ordinary shares trades on the Nasdaq Stock Market
What is the ticker symbol for Adagene Inc. - ADS, each representing 1.25 ordinary shares?
The ticker symbol for Adagene Inc. - ADS, each representing 1.25 ordinary shares is ADAG on the Nasdaq Stock Market
What is the current price of Adagene Inc. - ADS, each representing 1.25 ordinary shares?
The current price of Adagene Inc. - ADS, each representing 1.25 ordinary shares is 1.765
When was Adagene Inc. - ADS, each representing 1.25 ordinary shares last traded?
The last trade of Adagene Inc. - ADS, each representing 1.25 ordinary shares was at 05/23/25 01:06 PM ET
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.